SOURCE: SCYNEXIS, INC.

SCYNEXIS, Inc.

November 20, 2013 08:05 ET

SCYNEXIS Appoints Vivian Doelling as Vice President of Animal Health

Company Will Expand Animal Health Division and Advance Key Animal Health Candidates

RESEARCH TRIANGLE PARK, NC--(Marketwired - Nov 20, 2013) - Drug discovery company SCYNEXIS, Inc. today announced the appointment of Dr. Vivian Doelling as Vice President of Animal Health. Doelling is an industry leader in the field of animal health with more than 20 years of experience.

"Vivian's extensive background in animal health will play a key role in the development and growth of our animal health business, expanding our research beyond parasitology," said Dr. Yves Ribeill, SCYNEXIS president and chief executive officer. "Her contributions to SCYNEXIS will be important as we continue to expand our offerings to our animal health partners and to identify new drug candidates, such as SCY-641 for the treatment of canine keratoconjunctivitis sicca."

"I'm excited to be a part of the SCYNEXIS team and to have the opportunity to address animal health issues," said Doelling. "SCYNEXIS is dedicated to building out its Animal Health Division and I am ready to help the division realize its potential."

Doelling has more than two decades of experience in the creation and management of biological research and development operations for therapeutic proteins and vaccines for human and animal use. Previously, Doelling worked as a consultant for the biotechnology and animal health industries where her work concentrated in product development, technology assessment, IP portfolio management, licensing, commercialization and strategic planning. Prior to this, she was Vice President of Research and Development for Embrex, Inc. and Director of Research and Development after Pfizer Animal Health acquired Embrex.

About SCYNEXIS
SCYNEXIS is developing an innovative pipeline of proprietary technologies centered on our anti-fungal, anti-viral and animal health platforms. SCY-078 is the first oral glucan synthesis inhibitor being developed for the treatment of systemic fungal diseases and is a semi-synthetic derivative of the natural product enfumafungin. SCY-635 from our cyclophilin inhibitor platform is being developed for the treatment of viral diseases including Hepatitis C and Hepatitis B. Through our unique research and development expertise in animal health, we have a number of compounds in development with our partners including SCY-641 for the treatment of keratoconjunctivitis sicca. To learn more, visit www.scynexis.com

Contact Information

  • For further information about SCYNEXIS:
    Amanda Mancuso
    Chief of Staff
    SCYNEXIS, Inc.
    amanda.mancuso@scynexis.com
    Tel: +1 919 544 8663

    SCYNEXIS Media Contact:
    Rick Rountree
    Rountree Communications, Inc.
    rick@rickrountree.com
    Tel: +1 919 878 1144